Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5902414 | 0.93 | MAPT (0.77) | MAPTHTTRAB9ALMNAGAA | |
| SCHEMBL15350108 | 0.91 | HDAC1 (0.73) | MAPTHTTRAB9ALMNAHDAC1 | |
| SCHEMBL2356413 | 0.91 | HDAC1 (0.72) | MAPTHTTRAB9ALMNAGAA | |
| SCHEMBL3859340 | 0.88 | MAPT (0.60) | MAPTHTTRAB9ALMNAGAA | |
| SCHEMBL3061430 | 0.88 | MAPT (1.00) | MAPTHTTRAB9ALMNAGAA | |
| Hydrochloric Acid SCHEMBL27689202 | 0.86 | MAPT (0.96) | MAPTHTTRAB9ALMNAGAA | |
| SCHEMBL10953379 | 0.86 | HDAC1 (0.62) | MAPTHTTRAB9AGAAHDAC1 | |
| SCHEMBL13356363 | 0.85 | MAPT (0.80) | MAPTHTTRAB9ALMNAGAA | |
| SCHEMBL11705109 | 0.85 | TRPV1 (0.82) | MAPTHTTRAB9ALMNAGAA | |
| SCHEMBL27671467 | 0.85 | MAPT (0.86) | MAPTHTTRAB9ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110066254-B | Preparation method of isothiazole-3-ketone compound | 温州大学 | 2021-03-19 | — | — | CN | disclosed |
| EP-1898910-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-28 | — | — | EP | disclosed |
| WO-2014011663-A1 | INHIBITORS OF BACTERIAL DIGUANYLATE CYCLASE | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20130030017-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ANDRIES KOENRAAD JOZEF LODEWIJK MARCEL (BE) | 2013-01-31 | — | — | US | disclosed |
| CN-101252928-B | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA NV | 2012-05-23 | — | — | CN | disclosed |
| EP-2244721-A2 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO Ý1,2-C¨QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | Bayer Schering Pharma AG (DE) | 2010-11-03 | — | — | EP | disclosed |
| US-20100204270-A1 | Quinoline Derivatives as Antibacterial Agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-12 | — | — | US | disclosed |
| WO-2009091550-A2 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2009-07-23 | — | — | WO | disclosed |
| CN-101252928-A | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204270-A1 | Quinoline Derivatives as Antibacterial Agents | NQO2, NDUFB7, NQO1 | MAPT 334/4885HTT 3818/4885RAB9A 988/4885 |
| US-20130030017-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | NQO2, NDUFB7, NDUFA7 | MAPT 379/4885HTT 3775/4885RAB9A 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.